# OnCo record nct06556563 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06556563/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06556563", "NCT06556563" ;
  schema:name "EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma"@en ;
  schema:description "A phase 3 trial of Temozolomide and Pembrolizumab in glioma & glioblastoma, run by NovoCure GmbH, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06556563/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06556563> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2025-02-03" ;
  onco:cancers <https://onco.cc/cancers/glioblastoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/novocure/>, <https://onco.cc/companies/merck/> .